TransMedics Group, Inc.
TMDX
$67.08
-$0.57-0.84%
| Weiss Ratings | TMDX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Fair | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | C+ | |||
| Rating Factors | TMDX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Excellent | |||
| Efficiency Index | Fair | |||
| Solvency Index | Excellent | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | TMDX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 2.08 | |||
| Price History | TMDX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -3.25% | |||
| 30-Day Total Return | 0.08% | |||
| 60-Day Total Return | -0.42% | |||
| 90-Day Total Return | -24.20% | |||
| Year to Date Total Return | 0.87% | |||
| 1-Year Total Return | -20.80% | |||
| 2-Year Total Return | -8.12% | |||
| 3-Year Total Return | 293.66% | |||
| 5-Year Total Return | 461.81% | |||
| 52-Week High % Change | -61.86% | |||
| 52-Week Low % Change | 23.00% | |||
| Price | TMDX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $177.37 | |||
| 52-Week Low Price | $55.00 | |||
| 52-Week Low Price (Date) | Jan 21, 2025 | |||
| 52-Week High Price (Date) | Aug 23, 2024 | |||
| Valuation | TMDX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 2.28B | |||
| Enterprise Value | 2.46B | |||
| Price/Earnings (TTM) | 66.32 | |||
| Earnings Per Share (TTM) | 1.02 | |||
| Earnings Per Share Growth | -230.87% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 5.39 | |||
| Price/Book (Q) | 9.95 | |||
| Enterprise Value/Revenue (TTM) | 5.57 | |||
| Price | $67.08 | |||
| Enterprise Value/EBITDA (TTM) | 42.95 | |||
| Enterprise Value/EBIT | 65.58 | |||
| Market Cap Category | Mid Cap | |||
| Dividends and Shares | TMDX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 35.21M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | TMDX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 978 552 0900 | |||
| Address | 200 Minuteman Road Andover, MA 01810 | |||
| Website | www.transmedics.com | |||
| Country | United States | |||
| Year Founded | 1998 | |||
| Profitability | TMDX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | 8.49% | |||
| Profit Margin | 8.03% | |||
| Management Effectiveness | TMDX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | 3.10% | |||
| Return on Equity | 19.39% | |||
| Income Statement | TMDX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 441.54M | |||
| Total Revenue (TTM) | 441.54M | |||
| Revenue Per Share | $12.54 | |||
| Gross Profit (TTM) | 262.08M | |||
| EBITDA (TTM) | 57.25M | |||
| EBIT (TTM) | 37.50M | |||
| Net Income (TTM) | 35.46M | |||
| Net Income Avl. to Common (TTM) | 35.46M | |||
| Total Revenue Growth (Q YOY) | 49.83% | |||
| Earnings Growth (Q YOY) | 70.11% | |||
| EPS Diluted (TTM) | 1.02 | |||
| EPS Diluted Growth (Q YOY) | 76.83% | |||
| Balance Sheet | TMDX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 336.65M | |||
| Cash Per Share (Q) | $9.56 | |||
| Total Current Assets (Q) | 497.22M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 228.60M | |||
| Current Ratio (Q) | 8.299 | |||
| Book Value Per Share (Q) | $6.80 | |||
| Total Assets (Q) | 804.08M | |||
| Total Current Liabilities (Q) | 59.91M | |||
| Total Debt (Q) | 518.29M | |||
| Total Liabilities (Q) | 575.47M | |||
| Total Common Equity (Q) | 228.60M | |||
| Cash Flow | TMDX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -129.30M | |||
| Cash from Financing (TTM) | 22.87M | |||
| Net Change in Cash (TTM) | -58.16M | |||
| Levered Free Cash Flow (TTM) | -102.77M | |||
| Cash from Operations (TTM) | 48.80M | |||
